Moreover, the addition of dapagliflozin may facilitate the introduction of other HF drugs, as it may reduce the risk of adverse events (i.e., hyperkalemia with mineralocorticoid receptor antagonists is reduced with the concomitant use of dapagliflozin) [67]. This evidence concerns the gene NR3C2 and Hyperkalemia.